Last reviewed 2026-04-22 · How we verify

Zubsolv sublingual tablets

Zubsolv is a combination of buprenorphine and naloxone that binds to opioid receptors to reduce cravings and withdrawal symptoms in opioid use disorder.

Zubsolv is a combination of buprenorphine and naloxone that binds to opioid receptors to reduce cravings and withdrawal symptoms in opioid use disorder. Used for Opioid use disorder maintenance treatment.

At a glance

Mechanism of action

Buprenorphine is a partial mu-opioid receptor agonist that provides a ceiling effect on respiratory depression, making it safer than full opioid agonists. Naloxone is an opioid antagonist included to deter intravenous misuse. Together, they work to prevent withdrawal symptoms and reduce the reinforcing effects of illicit opioids.

Approved indications

• Opioid use disorder maintenance treatment

Common side effects

• Headache
• Nausea
• Constipation
• Insomnia
• Sweating
• Dizziness

Key clinical trials

• A Bundled Intervention - Phase 2 (PHASE4)
• Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation (PHASE4)
• Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (PHASE4)
• Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments (PHASE2, PHASE3)
• Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder (PHASE2)
• Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder (PHASE4)
• Medication Maintenance Therapy in Community Pharmacy Settings (PHASE2, PHASE3)
• XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.